Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Palobiofarma, Novartis deal

October 26, 2015 7:00 AM UTC

Palobiofarma granted Novartis exclusive, worldwide rights to develop and commercialize PBF-509. Palobiofarma said the adenosine A2A receptor (ADORA2A) antagonist is entering Phase I testing to treat non-small cell lung cancer (NSCLC). The company also granted Novartis rights to IP related to the role of adenosine in immunotherapy. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article